Related Experiment Video
Updated: Aug 8, 2025

Author Spotlight: Segmentation and VR for Advanced Neurovascular Interventions
Published on: April 5, 2024
SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches
Caitlin R Rausch1, Hagop M Kantarjian2, Elias J Jabbour2
1Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX.
Abstract:
Combination chemotherapy is the mainstay of treatment for acute lymphoblastic leukemia (ALL). The Hyper-CVAD regimen was developed in 1992 at MD Anderson Cancer Center and has since become a standard of care option for adult patients with ALL. Since its conception, a number of modifications have been implemented to customize the regimen for different patient populations and safely incorporate novel therapies without compromising tolerability. We aim to review the evolution of the Hyper-CVAD regimen over the past 3 decades, focusing on clinical pearls, as well as future directions.
More Related Videos
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Continuous Renal Replacement Therapy
Coronary Artery Disease IV: Preventive Measures

